Department of Dermatology, Seoul National University College of Medicine, Seoul National University Bundang Hospital, Gyeonggi Department of Dermatology, Chung-Ang University, Seoul, Korea.
J Eur Acad Dermatol Venereol. 2011 Feb;25(2):211-4. doi: 10.1111/j.1468-3083.2010.03758.x. Epub 2010 Jun 21.
Various treatments have been attempted for female pattern hair loss (FPHL), including topical minoxidil, oral antiandrogen and finasteride. But, there is no consensus on the standard treatment options. Clinical efficacy of finasteride in treating FPHL is still in controversy, but there is a tendency to high dose finasteride, which is more effective than lower dose.
The purpose of this study was to evaluate the clinical efficacy of high dose (5 mg/day) oral finasteride in normoandrogenic Asian women with FPHL.
Total of 87 normoandrogenic, pre and post-menopausal women with FPHL were enrolled in this study. They were treated with oral finasteride (Proscar(®)), 5 mg daily for 12 months. Efficacy was evaluated with hair density and thickness changes assessed by phototrichogram and global photographs using 7-point scale.
Eighty-six patients completed 12 months of finasteride treatment schedule. One patient (1.1%) withdrew due to headache. At initial visits, mean hair density was 90 ± 22/cm(2) and mean hair thickness was 64 ± 11 μm. After 12 months of finasteride treatment, hair density was significantly increased to 107 ± 23/cm(2) (P<0.001), and hair thickness was also significantly increased to 70 ± 9 μm (P=0.02). In global photographs, 70 (81.4%) of the 86 patients were improved (57 were slightly, 10 were moderately and four were greatly improved). Patients without any changes were 13 (15.1%) and 3 (3.5%) patients reported slightly aggravated. Four patients (4.6%) reported adverse events (headache, menstrual irregularity, dizziness and increased body hair growth). However, these adverse events were mild and disappeared soon.
Oral finasteride, 5 mg/day, may be an effective and safe treatment for normoandrogenic women with FPHL.
各种治疗方法已被尝试用于女性型脱发(FPHL),包括局部米诺地尔、口服抗雄激素和非那雄胺。但是,对于标准治疗方案尚无共识。非那雄胺治疗 FPHL 的临床疗效仍存在争议,但存在使用高剂量非那雄胺的趋势,其效果优于低剂量。
本研究旨在评估高剂量(5 毫克/天)口服非那雄胺治疗 FPHL 的临床疗效。
共纳入 87 例雄激素正常的绝经前和绝经后 FPHL 女性患者,接受口服非那雄胺(保法止®)治疗,每日 5 毫克,疗程 12 个月。通过毛发密度和厚度变化的光电图和 7 分制整体照片评估疗效。
86 例患者完成了 12 个月的非那雄胺治疗方案。1 例患者(1.1%)因头痛而退出。初始就诊时,平均毛发密度为 90±22/cm²,平均毛发厚度为 64±11 μm。经 12 个月的非那雄胺治疗后,毛发密度显著增加至 107±23/cm²(P<0.001),毛发厚度也显著增加至 70±9 μm(P=0.02)。在整体照片中,86 例患者中有 70 例(81.4%)得到改善(57 例略有改善,10 例中度改善,4 例明显改善)。13 例(15.1%)患者无任何变化,3 例(3.5%)患者报告略有加重。4 例(4.6%)患者报告出现不良反应(头痛、月经不规律、头晕和体毛增多)。然而,这些不良反应均为轻度且很快消失。
口服非那雄胺,5 毫克/天,可能是治疗雄激素正常的 FPHL 女性的一种有效且安全的方法。